Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA cites Baxter for misleading Feiba promotion

This article was originally published in Scrip

Executive Summary

A promotional email for Baxter Healthcare's haemophilia treatment Feiba VH makes misleading safety and efficacy claims, the US FDAsaid. A "clinical thank you email" for the anti-inhibitor coagulant complex claims a 60% efficacy rate with one infusion, but this is inconsistent with the product's labelling. The promotion also minimises the fact that serious thrombotic events can occur with Feiba, and reported adverse events do not support the email's claim that Feiba is "well tolerated in 96-100% of infusions". Baxter said the email was a one-time communication used last year. The company is working to address the agency's concerns and ensure that appropriate contextual information is included in promotions to adequately support safety and efficacy claims.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC001002

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel